BioAge Labs, Inc. (BIOA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$5.10-7.78%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge BioAge Labs, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.22M
EPS	—	-0.683
Annual ending 2026-12-31
Revenue	—	7.57M
EPS	—	-2.463
Annual ending 2027-12-31
Revenue	—	14.88M
EPS	—	-2.26

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
improve net income towards profitability	BioAge Labs aims to improve cash flow and net income from current losses.	Under Pressure	net income loss widens or EPS falls below -0.52 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
achieve positive cash flow from operations	Management targets positive cash flow and better net income, with revenue growth from new products.	Under Pressure	cash from operating activities remains negative throughout FY26	Cash from operations: $-19.26M FY2026-Q2; GAAP. Published target: >= $0 cash from operating activities. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-19,260,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
increase revenue through new products and market expansion	Management targets positive cash flow and better net income, with revenue growth from new products.	Broken	revenue declines below $2.77M per quarter over next year	Revenue: $2.451M FY2026-Q2; GAAP. Published target: revenue grows or stabilizes above $2.77M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 5, 20262,451,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: eab869a4-6afc-426b-b82d-7fc8b38627ee. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.26

$-2.04 → $-2.26 · observed estimates

FY2027 revenue$0.01B

$0.04B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.04	$35,951,100	7 / 10
2026-07-25	$-2.04	$35,951,100	7 / 10
2026-07-26	$-2.04	$35,951,100	7 / 10
2026-07-27	$-1.86	$35,951,730	6 / 7
2026-07-28	$-2.04	$35,951,100	7 / 10
2026-07-29	$-2.04	$35,951,100	7 / 10
2026-07-30	$-2.04	$35,951,100	7 / 10
2026-07-31	$-2.04	$35,951,100	7 / 10
2026-08-01	$-2.04	$35,951,100	7 / 10
2026-08-02	$-2.45	$17,831,700	7 / 10
2026-08-03	$-2.45	$17,831,700	7 / 10
2026-08-04	$-2.45	$17,831,700	7 / 10
2026-08-05	$-2.45	$17,831,700	7 / 10
2026-08-06	$-2.45	$17,831,700	7 / 10
2026-08-07	$-2.09	$17,832,860	6 / 7
2026-08-08	$-2.41	$17,299,440	7 / 9
2026-08-09	$-2.41	$17,299,440	7 / 9
2026-08-10	$-2.41	$17,299,440	7 / 9
2026-08-11	$-2.36	$15,672,900	7 / 10
2026-08-12	$-2.36	$15,672,900	7 / 10
2026-08-13	$-2.36	$15,672,900	7 / 10
2026-08-14	$-2.09	$17,832,860	6 / 7
2026-08-15	$-2.09	$17,832,860	6 / 7
2026-08-16	$-2.09	$17,832,860	6 / 7
2026-08-17	$-2.09	$17,832,860	6 / 7
2026-08-18	$-2.09	$17,832,860	6 / 7
2026-08-19	$-2.09	$17,832,860	6 / 7
2026-08-20	$-2.14	$15,671,000	6 / 7
2026-08-21	$-2.14	$15,671,000	6 / 7
2026-08-22	$-2.14	$15,671,000	6 / 7
2026-08-23	$-2.14	$15,671,000	6 / 7
2026-08-24	$-2.14	$15,671,000	6 / 7
2026-08-25	$-2.14	$15,671,000	6 / 7
2026-08-26	$-2.14	$15,671,000	6 / 7
2026-08-27	$-2.14	$15,671,000	6 / 7
2026-08-28	$-2.14	$15,671,000	6 / 7
2026-08-29	$-2.14	$15,671,000	6 / 7
2026-08-30	$-2.14	$15,671,000	6 / 7
2026-08-31	$-2.14	$15,671,000	6 / 7
2026-09-01	$-2.14	$15,671,000	6 / 7
2026-09-02	$-2.14	$15,671,000	6 / 7
2026-09-03	$-2.14	$15,671,000	6 / 7
2026-09-04	$-2.14	$15,671,000	6 / 7
2026-09-05	$-2.14	$15,671,000	6 / 7
2026-09-06	$-2.14	$15,671,000	6 / 7
2026-09-07	$-2.14	$15,671,000	6 / 7
2026-09-08	$-2.14	$15,671,000	6 / 7
2026-09-09	$-2.14	$15,671,000	6 / 7
2026-09-10	$-2.17	$15,671,000	6 / 7
2026-09-11	$-2.17	$15,671,000	6 / 7
2026-09-12	$-2.17	$15,671,000	6 / 7
2026-09-13	$-2.17	$15,671,000	6 / 7
2026-09-14	$-2.17	$15,671,000	6 / 7
2026-09-15	$-2.17	$15,671,000	6 / 7
2026-09-16	$-2.17	$15,671,000	6 / 7
2026-09-17	$-2.17	$15,671,000	6 / 7
2026-09-18	$-2.17	$15,671,000	6 / 7
2026-09-19	$-2.17	$15,671,000	6 / 7
2026-09-20	$-2.17	$15,671,000	6 / 7
2026-09-21	$-2.17	$15,671,000	6 / 7
2026-09-22	$-2.17	$15,671,000	6 / 7
2026-09-23	$-2.17	$15,671,000	6 / 7
2026-09-24	$-2.17	$15,671,000	6 / 7
2026-09-25	$-2.17	$15,671,000	6 / 7
2026-09-26	$-2.17	$15,671,000	6 / 7
2026-09-27	$-2.17	$15,671,000	6 / 7
2026-09-28	$-2.17	$15,671,000	6 / 7
2026-09-29	$-2.17	$15,671,000	6 / 7
2026-09-30	$-2.17	$15,671,000	6 / 7
2026-10-01	$-2.17	$15,671,000	6 / 7
2026-10-02	$-2.17	$15,671,000	6 / 7
2026-10-03	$-2.17	$15,671,000	6 / 7
2026-10-04	$-2.17	$15,671,000	6 / 7
2026-10-05	$-2.17	$15,671,000	6 / 7
2026-10-06	$-2.17	$15,671,000	6 / 7
2026-10-07	$-2.17	$15,671,000	6 / 7
2026-10-08	$-2.17	$15,671,000	6 / 7
2026-10-09	$-2.17	$15,671,000	6 / 7
2026-10-10	$-2.17	$15,671,000	6 / 7
2026-10-11	$-2.17	$15,671,000	6 / 7
2026-10-12	$-2.17	$15,671,000	6 / 7
2026-10-13	$-2.24	$14,882,727	7 / 8
2026-10-14	$-2.27	$14,882,727	7 / 8
2026-10-15	$-2.27	$14,882,727	7 / 8
2026-10-16	$-2.26	$14,882,727	7 / 8
2026-10-17	$-2.26	$14,882,727	7 / 8
2026-10-18	$-2.26	$14,882,727	7 / 8
2026-10-19	$-2.26	$14,882,727	7 / 8
2026-10-20	$-2.26	$14,882,727	7 / 8
2026-10-21	$-2.26	$14,882,727	7 / 8
2026-10-22	$-2.26	$14,882,727	7 / 8
2026-10-23	$-2.26	$14,882,727	7 / 8
2026-10-24	$-2.26	$14,882,727	7 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	2
2026-06-01	7	2
2026-07-01	7	2
2026-08-01	7	2
2026-09-01	7	2
2026-10-01	7	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 11

$8.00New observation · no comparable prior

$0$4.40$8.80

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

improve net income towards profitabilityPublished status: Under Pressure
achieve positive cash flow from operationsPublished status: Under Pressure
increase revenue through new products and market expansionPublished status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-80.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

BioAge Labs, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

BIOA is a speculative clinical-stage biotech, with its longer-term case tied to clinical progress rather than established earnings. The thesis is on watch: management priorities are progressing, but recent financial performance is weak and the risk label has risen to high.

What's priced into BioAge Labs, Inc.

The valuation model shows BIOA at a premium to peers, with optionality as the main valuation driver. Its expectations gap is strongly negative, which suggests expectations are demanding relative to the model, though confidence in that estimate is low; the priced-in label is justified and no fragility gates fired.

What the fundamentals likely do

In the near term, BIOA is likely to remain loss-making as R&D spending rises, while collaboration revenue has grown over time but eased from the prior quarter. Management has advanced BGE-102, including the first participant dosed in the QUELL-CV Phase 2 trial, and estimates current cash can fund operations through 2029. Near-term execution risk remains high, with a meaningful chance of a miss and a possible guidance cut to watch for.

What BioAge Labs, Inc. hinges on

The multi-year thesis hinges on clinical progress and useful data from BGE-102, alongside keeping enough cash to fund development. A guidance cut or further weakening in jobs data could add pressure to the business outlook, while strong results and higher guidance from healthcare bellwethers could support sector momentum.